These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 33371704)

  • 21. Inflammatory Bowel Disease in the COVID-19 Pandemic: the Patients' Perspective.
    Grunert PC; Reuken PA; Stallhofer J; Teich N; Stallmach A
    J Crohns Colitis; 2020 Dec; 14(12):1702-1708. PubMed ID: 32564068
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics of Infliximab and Reduction of Treatment for Inflammatory Bowel Diseases.
    Williet N; Paul S; Peyrin-Biroulet L; Roblin X
    Dig Dis Sci; 2016 Apr; 61(4):990-5. PubMed ID: 26669880
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of Rapid vs Standard Infliximab Infusions in the Pediatric Population.
    Rozette NA; Hellauer CM; McKee C; Vazifedan T; Gabriel CA; Dice JE; Yokois NU
    Inflamm Bowel Dis; 2018 Aug; 24(9):2007-2014. PubMed ID: 29788416
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Selective Use of Combination Therapy in Patients With Infliximab-resistant Inflammatory Bowel Disease: Data From a Tertiary Referral Center.
    Orlando A; Renna S; Rizzuto G; Orlando E; Affronti M; Cottone M
    Clin Gastroenterol Hepatol; 2016 Jun; 14(6):914. PubMed ID: 26707682
    [No Abstract]   [Full Text] [Related]  

  • 25. Improved Long-term Outcomes of Patients With Inflammatory Bowel Disease Receiving Proactive Compared With Reactive Monitoring of Serum Concentrations of Infliximab.
    Papamichael K; Chachu KA; Vajravelu RK; Vaughn BP; Ni J; Osterman MT; Cheifetz AS
    Clin Gastroenterol Hepatol; 2017 Oct; 15(10):1580-1588.e3. PubMed ID: 28365486
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Does infliximab short infusion have a beneficial impact on the quality of life in patients with inflammatory bowel diseases? A single centre prospective evaluation.
    Principi M; Losurdo G; La Fortezza RF; Lopolito P; Lovero R; Grillo S; Bringiotti R; Ierardi E; Di Leo A
    J Gastrointestin Liver Dis; 2015 Jun; 24(2):165-70. PubMed ID: 26114175
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adherence to Infliximab Treatment in a Pediatric Inflammatory Bowel Disease Cohort.
    Vitale DS; Greenley RN; Lerner DG; Mavis AM; Werlin SL
    J Pediatr Gastroenterol Nutr; 2015 Oct; 61(4):408-10. PubMed ID: 25885878
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety, efficacy and pharmacokinetics of vedolizumab in patients with simultaneous exposure to an anti-tumour necrosis factor.
    Ben-Horin S; Ungar B; Kopylov U; Lahat A; Yavzori M; Fudim E; Picard O; Peled Y; Eliakim R; Del Tedesco E; Paul S; Roblin X
    Aliment Pharmacol Ther; 2018 Apr; 47(8):1117-1125. PubMed ID: 29446098
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Management of Biological Therapy Before Elective Inflammatory Bowel Disease Surgeries.
    Hansen TM; Targownik LE; Karimuddin A; Leung Y
    Inflamm Bowel Dis; 2019 Sep; 25(10):1613-1620. PubMed ID: 30794289
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment Adherence and Clinical Outcomes of Patients with Inflammatory Bowel Disease on Biological Agents During the SARS-CoV-2 Pandemic.
    Iborra I; Puig M; Marín L; Calafat M; Cañete F; Quiñones C; González-González L; Cardona G; Mañosa M; Domènech E
    Dig Dis Sci; 2021 Dec; 66(12):4191-4196. PubMed ID: 33469807
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Introduction.
    Gearry RB
    J Gastroenterol Hepatol; 2016 Jun; 31 Suppl 1():23. PubMed ID: 27273032
    [No Abstract]   [Full Text] [Related]  

  • 32. Maintenance therapy with infliximab or vedolizumab in IBD is not associated with increased SARS-CoV-2 seroprevalence: UK experience in the 2020 pandemic.
    McGregor CG; Adams A; Sadler R; Arancibia-Cárcamo CV; Palmer R; Ambrose T; Brain O; Walsh A; Klenerman P; Travis SP; Croft NM; Lindsay JO; Satsangi J
    Gut; 2021 Dec; 70(12):2398-2400. PubMed ID: 33579788
    [No Abstract]   [Full Text] [Related]  

  • 33. [Treatment adherence and use of complementary and alternative medicine in patients with inflammatory bowel disease].
    Lakatos L; Czeglédi Z; Dávid G; Kispál Z; Kiss LS; Palatka K; Kristóf T; Molnár T; Salamon A; Demeter P; Miheller P; Szamosi T; Banai J; Papp M; Bene L; Kovács A; Rácz I; Lakatos PL
    Orv Hetil; 2010 Feb; 151(7):250-8. PubMed ID: 20133244
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Variation in infliximab administration practices in the treatment of pediatric inflammatory bowel disease.
    Adler J; Sandberg KC; Shpeen BH; Eder SJ; Dhanani M; Clark SJ; Freed GL
    J Pediatr Gastroenterol Nutr; 2013 Jul; 57(1):35-8. PubMed ID: 23459317
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inflammatory bowel disease: adherence to immunomodulators in a biological therapy era.
    Campos S; Portela F; Sousa P; Sofia C
    Eur J Gastroenterol Hepatol; 2016 Nov; 28(11):1313-9. PubMed ID: 27501126
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Influence of combination therapy with immune modulators on anti-TNF trough levels and antibodies in patients with IBD.
    van Schaik T; Maljaars JP; Roopram RK; Verwey MH; Ipenburg N; Hardwick JC; Veenendaal RA; van der Meulen-de Jong AE
    Inflamm Bowel Dis; 2014 Dec; 20(12):2292-8. PubMed ID: 25230167
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Objective versus subjective assessment of oral medication adherence in pediatric inflammatory bowel disease.
    Hommel KA; Davis CM; Baldassano RN
    Inflamm Bowel Dis; 2009 Apr; 15(4):589-93. PubMed ID: 18985746
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Infliximab for very early-onset inflammatory bowel disease: A tertiary center experience in Japan.
    Takeuchi I; Kaburaki Y; Arai K; Shimizu H; Hirano Y; Nagata S; Shimizu T
    J Gastroenterol Hepatol; 2020 Apr; 35(4):593-600. PubMed ID: 31425641
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adherence to infliximab therapy in inflammatory bowel disease patients in a real-life setting.
    Martelli L; Lopez A; Strobel S; Danese S; Roblin X; Baumann C; Peyrin-Biroulet L
    J Dig Dis; 2017 Oct; 18(10):566-573. PubMed ID: 28858439
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Individualized Infliximab Treatment Guided by Patient-managed eHealth in Children and Adolescents with Inflammatory Bowel Disease.
    Carlsen K; Houen G; Jakobsen C; Kallemose T; Paerregaard A; Riis LB; Munkholm P; Wewer V
    Inflamm Bowel Dis; 2017 Sep; 23(9):1473-1482. PubMed ID: 28617758
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.